NCT02892734: A reported trial by Northwestern University
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02892734 |
|---|---|
| Title | A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 18, 2017 |
| Completion date | Feb. 4, 2019 |
| Required reporting date | Feb. 4, 2020, midnight |
| Actual reporting date | May 1, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |